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sixteen pixellated LYSO crystals, coupled to multi-anode 
PhotoMultiplier, provides the particle energy measurement. 
The front-end electronics is composed of 4096 channels, and 
the read-out is performed by 128 ASICs (BASIC32_ADC) 
specifically designed for SiPMs read-out application [1], while 
trigger system and data acquisition are implemented with a 
system of 21 FPGAs.  
The detector design and optimization of the detector have 
been performed using Monte Carlo (MC) simulations based on 
the results of experimental measurements ([2], [3]). The DP 
hardware features of DP will be reviewed. The expected 
performance, as resulting from the MC, will be discussed in 
the clinical application framework. 
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We present an isocentric, carbon/proton superconducting 
and permanent magnet proton gantries, respectively, with a 
fixed magnetic field but very large momentum acceptance. 
During a treatment it is possible to do longitudinal and 
transverse spot scanning for the whole energy range 
required. The size and cost are dramatically reduced; for 
example compared to the weight of the Heidelberg 630 tons 
the weight is estimated to be about one tons. The proton 
gantry is of a size of the present PSI gantry, but it is made of 
small permanent Halbach magnets. It can transport very 
precisely the proton beam within a 30-250 MeV kinetic 
energy range, under the permanent magnetic field, with 
variation of the scanning magnets only with an infinite S.A.D.  
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As opposed to surgical disciplines, radiation oncology relies 
on non-invasive imaging of the target volume (tumor, lymph 
nodes or metastases). Apart from anatomical imaging for 
target volume delineation (e.g., CT, MRI), functional imaging 
(e.g., PET, functional CT and MRI) is increasingly being 
integrated in modern radiotherapy techniques. Functional 
imaging is used prior to therapy for guidance, dose-escalation 
strategies and treatment selection, but also early during 
irradiation for response monitoring and consequently 
treatment adaptation. Moreover, functional imaging is 
incorporated in the radiotherapy chain for identification of 
patients at increased risk of normal tissue complications 
(e.g., SPECT and CT for prediction of radiation pneumonitis). 
This presentation will present the current status of functional 
imaging for radiation oncology prior to and during treatment, 
both for the target volume and normal tissues. 
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As compared to photon beams, charged particle therapy such 
as both proton beam therapy (PBT) and carbon-ion 
radiotherapy (CIRT) offers improved dose distribution, 
localizing sufficient dose within a target volume while 
minimizing the dose to the surrounding normal tissues. In 
addition, carbon-ions being heavier than protons provide a 
higher radiobiological effectiveness (RBE), which increases 
with depth reaching the maximum at the end of the beam's 
range. This theoretically is an ideal property from the 
standpoint of cancer radiotherapy.  
In Japan, PBT and CIRT were both initiated at NIRS in 1979 
and 1983, respectively. Since then, various types of tumors 
have been prospectively treated. As of December 2015, there 
are a total of 13 charged particle therapy facilities in 
operation including 9 for PBT and 4 for CIRT.  Several other 
facilities are under construction or being planned for either 
PBT or CIRT. In 2003, we established JCPT (Japan Clinical 
Study Group of Particle Therapy) for the purpose of changing 
information and improving therapeutic techniques for 
charged particle therapy, as well as collecting clinical data 
from existing facilities in Japan. According to the survey of 
JCPT, a total of 30,850 patients were treated in Japan from 
1979 to 2014, including 17,858 patients (58%) with PBT and 
12,922 patients (42%) with CIRT. Male/female was 73%/27%. 
The age of the patients ranging <51, 51-60, 61-70, 71-80, >80 
was 12%, 17%, 34%, 29%, and 8%, respectively. As with the 
tumor types, the major tumors for PBT were prostate (30%), 
liver (19%), H&N (13%), lung (12%), GI (6%) and pancreas (4%), 
and those for CIRT were prostate (24%), H&N (14%), B&S 
(11%), lung (11%), liver (10%) and rectum/pancreas (5% 
each).  
Among 4 facilities for CIRT, the largest numbers of patients 
were treated at NIRS, starting CIRT in 1994 using HIMAC 
(Heavy-ion medical accelerator in Chiba). More than 9,000 
patients have been so far treated based on > 70 protocols, by 
which the benefit of CIRT over other modalities has been 
demonstrated in locally, advanced tumors and non-squamous 
cell types of tumors. Based on their unique biophysical 
characteristics, a significant reduction in overall time and 
fraction has been achieved with minor toxicities. This 
included a single-fraction RT for early-stage NSCLC, one or 
two-fraction RT for liver cancer and 12-fraction RT for 
prostate cancer. Even for other tumors, CIRT with 16 or 
 
Figure 6: Tracker and calorimeter detectors 
